Anaplastic thyroid cancer: high-dose RT slows locoregional progression

  • Fan D & al.
  • Cancer
  • 8 Oct 2019

  • curated by Brian Richardson, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Higher-dose radiotherapy (RT) is associated with improved locoregional PFS (LPFS) and OS of patients with anaplastic thyroid cancer (ATC).

Why this matters

  • This study may help guide treatment of patients with this aggressive form of thyroid cancer.

Key results

  • 1-year LPFS was 74.4%; 1-year OS was 34.4%.
  • RT ≥60 Gy was associated with improved LPFS (87.2% vs 55.3%; HR, 0.135; P=.001) and OS (47.9% vs 17.4%; HR, 0.487; P=.004) compared with RT dose
  • Trimodal therapy (surgical resection, chemotherapy, and RT with dose ≥60 Gy) was associated with improved LPFS (85.9% vs 54.1%; HR, 0.060; P=.017) compared with other treatment regimens.
  • Grade 3 dermatitis was experienced by 20% of patients and grade 3 mucositis was experienced by 13% of patients.

Study design

  • 104 patients with ATC, 29.8% with metastatic disease, who received curative-intent or postoperative RT were included.
  • Funding: NIH/NCI, Marie-Josée and Henry R. Kravis Center for Molecular Oncology.

Limitations

  • Retrospective study.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit